Kura Oncology (KURA) Total Liabilities (2010 - 2026)

Kura Oncology (KURA) has 17 years of Total Liabilities data on file, last reported at $544.7 million in Q1 2026.

• Quarterly Total Liabilities rose 43.58% year-over-year to $544.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $544.7 million (up 43.58% YoY) and the FY2025 annual result came in at $564.2 million, up 62.83% from the prior year.
• Total Liabilities declined to $544.7 million in Q1 2026 per KURA's latest filing, from $564.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $564.2 million in Q4 2025 and bottomed at $21.9 million in Q2 2022.
• The 5-year median for Total Liabilities is $49.0 million (2024), against an average of $178.9 million.
• The widest annual swing landed in 2022, when Total Liabilities sank 34.84%; it then jumped 676.99% in 2025.
• Tracing KURA's Total Liabilities over 5 years: stood at $36.0 million in 2022, then surged by 43.39% to $51.7 million in 2023, then soared by 570.74% to $346.5 million in 2024, then jumped by 62.83% to $564.2 million in 2025, then fell by 3.47% to $544.7 million in 2026.
• Per Business Quant, the three latest KURA Total Liabilities figures stand at $544.7 million (Q1 2026), $564.2 million (Q4 2025), and $406.8 million (Q3 2025).

Peer Comparison